Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.
A huge study of Pfizer's blockbuster vaccine against pneumonia and other bacterial infections in...
The National Advertising Division--an industry regulatory agency administered by the Council of...
Pfizer has announced top-line results of a double-blind Phase 4 study evaluating the safety and...
Pfizer has announced that the European Commission approved an expanded indication for the use of Prevenar 13 for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older.
The accelerated stock buyback is part of its $11B share repurchase plan authorized in October. It said it will receive the approximately 150 million shares involved in the buyback from Goldman Sachs on Wednesday.
The Hospira deal will add significant value to Pfizer’s GEP segment, a vertical which has been rumored to be sold or spun-off as a separate entity. This somewhat mirrors Pfizer’s strategic objective to focus on core growth platforms in the branded drug market while divesting its ancillary operations, similar to when it carved-out its Animal Health business and brought it public.
Pfizer is buying Hospira for approximately $15.23 billion, saying it is a good fit with its established global pharmaceutical business. The buyout will also help Pfizer tap into the growing market for biosimilars, which are cheaper versions of biologic drugs that are used to treat conditions such as anemia.
Pfizer anounced the FDA has granted accelerated approval of IBRANCE®, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
Pfizer's fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research spending and legal costs also hurt the bottom line. The world's second-biggest drugmaker by revenue reported lower sales for most of its huge portfolio of prescription medicines, with the biggest hit coming from new generic competition to popular painkiller Celebrex.
Pfizer on Tuesday reported fourth-quarter earnings of $1.23B. On a per-share basis, the company said it had net income of 19 cents. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 54 cents per share.
The first in a new class of cancer medicines, Pfizer's Ibrance, appears poised for approval to treat advanced breast cancer within just a few months and could quickly become a blockbuster, some analysts believe.
Pfizer has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate.
Pfizer has announced top-line results from a double-blind Phase III study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherapeutic neuralgia (pain after shingles or PHN).
Pfizer has announced enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness.
Under the terms of the agreement, OPKO will receive an upfront payment of $295M and is eligible to receive up to an additional $275M upon the achievement of certain regulatory milestones. Pfizer will receive the exclusive license to commercialize hGH-CTP worldwide.
Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, has entered into a global collaboration with Pfizer for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus vectors for the potential treatment of hemophilia B.
The World Anti-Doping Agency has signed a deal with Pfizer to share information about new performance-enhancing substances that could be misused by athletes.
A new survey reveals that 77 percent of working women with breast cancer, including those with metastatic disease, feel that working aids in their recovery – a view shared almost unanimously by healthcare professionals, who were also surveyed (92%).
Pfizer has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.
Merck announced today that it has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.
Missouri House Speaker Tim Jones on Wednesday created a committee of lawmakers to review allegations that Attorney General Chris Koster has been influenced by lobbyist perks and campaign contributions.
Pfizer announced that the FDA has granted accelerated approval of TRUMENBA ® (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
On a per-share basis, the New York-based company said it had profit of 42 cents. Earnings, adjusted for non-recurring costs and to account for discontinued operations, were 57 cents per share.
Pfizer says it approved the repurchase of $11 billion in company stock. The company did not say when it would buy back the shares. Pfizer has $1.3 billion remaining from its latest stock repurchase program.
Pfizer announced that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021.
The U.S. Food and Drug Administration says it has approved new labeling for another opioid designed to limit painkiller abuse. The FDA said Friday that Pfizer Inc.'s Embeda can have labeling indicating that it has properties expected to reduce abuse of the drug when it is crushed and taken orally or snorted.
Federal health advisers say a bold-letter warning about suicide risks with Pfizer's Chantix should remain on the anti-smoking drug until it can reevaluated based on new, rigorous study information. Eleven advisers to the Food and Drug Administration voted to retain the so-called black box warning.
Federal regulators say Pfizer has provided low-quality evidence to support its request to remove a bold-letter warning from its anti-smoking drug Chantix about suicidal behavior. The twice-a-day tablet has carried the FDA's strongest warning label, known as a black box, since 2009 following reports of suicidality, hostility and depression among some patients.
- Page 1